GoodRx Holdings, Inc. Research And Development Expense

• GoodRx Holdings, Inc. showed a decrease of -2.2% in Research And Development Expense from 2024 to 2025.
• This data is from GoodRx Holdings, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
• XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 8 years of available data (2018 to 2025), GoodRx Holdings, Inc.'s Research And Development Expense has grown by 175.7%.
• Historical annual values: Fiscal year 2025: $121.03 million | Fiscal year 2024: $123.75 million | Fiscal year 2023: $135.84 million | Fiscal year 2022: $143.14 million | Fiscal year 2021: $125.86 million | Fiscal year 2020: $61.82 million | Fiscal year 2019: $29.30 million | Fiscal year 2018: $43.89 million.
• Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: June 20, 2026